Open an account

Senestech

SNES · NASDAQ

$0.6893−$0.0107 (−1.53%)TodayMarket closed ·
Prev close $0.70

About SNES

SenesTech, Inc. engages in the development and commercialization of proprietary technology for the management of animal pest populations. The company is headquartered in Surprise, Arizona and currently employs 23 full-time employees. The company went IPO on 2016-12-08. The Company’s product lines of fertility control products are: ContraPest, Evolve Rat, and Evolve Mouse. Its product, ContraPest, is a liquid bait containing the active ingredients 4-vinylcyclohexene diepoxide (VCD) and triptolide. ContraPest targets the reproductive systems of both male and female Norway and roof rats beginning with the first breeding cycle following consumption, which can lead to sustained reductions in the rat population. The Evolve Rat is a soft bait product that contains the active ingredient, cottonseed oil, which reduces fertility in both male and female rats. The Evolve Mouse, a modified version of soft bait technology containing the active ingredient cottonseed oil, which limits reproduction of male and female mice after one to two breeding cycles following consumption.

Employees
23
Headquarters
Surprise, Arizona
Listed
Dec 8, 2016
Sector
Health Care
Industry
Pharmaceuticals
Website
senestech.com

SNES key statistics

Market cap
3.74M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
3.13M
Volume
421.56K
Open price
$0.72
High today
$0.72
Low today
$0.6597
52 Week high
$4.04
52 Week low
$0.55

Senestech (SNES) at a glance

Senestech (SNES) last traded at $0.6893, with a market cap of 3.74M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.6597 and $0.72. The current price is 4.5% above the day's low and 4.3% below its high.

Volume so far is 421.56K shares, below the average of 3.13M shares a day.

Over the past year Senestech has ranged from $0.55 to $4.04, and now sits 4% of the way up that range.

Senestech met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.35 per share against an estimate of -$0.3723.

SNES earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 16.3% on average.

  1. Q2 FY24: reported -$3.08 per share against an estimate of -$3.26
  2. Q3 FY24: reported -$2.07 per share against an estimate of -$3.26
  3. Q4 FY24: reported -$1.22 per share against an estimate of -$1.53
  4. Q2 FY25: reported -$0.87 per share against an estimate of $0.00
  5. Q3 FY25: reported -$0.28 per share against an estimate of -$0.357
  6. Q4 FY25: reported -$0.35 per share against an estimate of -$0.306
  7. Q1 FY26: reported -$0.31 per share against an estimate of -$0.3366
  8. Q2 FY26: reported -$0.35 per share against an estimate of -$0.3723

SNES news

  • Press releasePRNewswire

    GLENBROOK CROSSES 30% OWNERSHIP OF SENESTECH

  • Press releasePRNewswire

    SenesTech Reports Record Preliminary Third Quarter Revenue Exceeding $1 Million, the Highest in Company History, with 40% Sequential Growth

  • Press releasePRNewswire

    SenesTech Expands Third-Party E-commerce Distribution with Grove Collaborative, Bringing Evolve® Rodent Birth Control™ Products to Sustainability-Focused Consumers

  • Press releasePRNewswire

    SenesTech to Participate in the Lytham Partners Fall 2026 Investor Conference

  • Press releasePRNewswire

    Swampscott Municipal Integrated Pest Management Program Achieves 43% Reduction in Rodent Activity with Evolve® Rat

  • Press releasePRNewswire

    SenesTech Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  • Press releasePRNewswire

    SenesTech to Participate in the Lytham Partners 2026 Consumer & Technology Investor Summit on August 18, 2026

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

Similar companies

Companies in the same industry as Senestech

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.